High-intensity brain stimulation to help with alcohol use disorder
Official title: High Intensity Alternating Current Stimulation as a Neuromodulation Therapy for Alcohol Use Disorder: A Pilot Study
Run by Shanghai Mental Health Center · NCT07227545 · Data updated 2026-11-12
This pilot study tests whether high-intensity transcranial alternating current stimulation (HI-tACS) can help reduce cravings and improve self-control in adults with alcohol use disorder.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Shanghai Mental Health Center Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | October 11, 2026 |
| Main results expected | November 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT07227545 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-60 with a DSM-5 diagnosis of Alcohol Use Disorder who can complete questionnaires and imaging procedures and have no contraindications to MRI.
✕Probably not a fit
Individuals with significant comorbid psychiatric or neurological conditions or those unable to tolerate MRI procedures may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This one-arm pilot study examines the preliminary effects of a two-week course of high-intensity transcranial alternating current stimulation (HI-tACS) on adults with alcohol use disorder. Participants will receive HI-tACS and undergo clinical assessments, EEG, and MRI before and after the intervention to explore changes in craving, self-regulation, decision-making, and brain activity. The goal is to generate initial clinical and mechanistic data to inform future research on HI-tACS as a neuromodulation therapy for AUD. The study also evaluates tolerability and safety in this population. MRI contraindications and other exclusion criteria ensure participant safety throughout the imaging protocol.
Why it matters
Potential benefit: If successful, HI-tACS could offer a non-invasive option to reduce cravings and improve cognitive-control in AUD.
How similar studies have gone: Previous neuromodulation studies in AUD have shown mixed results; this pilot will provide initial feasibility and mechanistic insights for HI-tACS in AUD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Education level of junior high school or above, capable of completing questionnaires and behavioral tests; * Aged 18-60 years; * Meet DSM-5 diagnostic criteria for Alcohol Use Disorder; * No abnormal findings on physical examination; * Agree to participate in follow-up assessments; * No contraindications for MRI scanning. Exclusion criteria: * Have impaired intelligence (Intelligence Quotient\<70); * Prior tDCS or TMS treatment within the past 3 months; * Contraindications for TMS therapy (e.g., intracranial metal implants, history of traumatic brain injury, skull defects, cardiac pacemakers, cardiovascular diseases, or epilepsy); * Severe somatic diseases or major organ dysfunction; * Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders). * Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders). * Diagnosis of other substance-related and addictive disorders or behavioral addictions.
Where it's running
-
Shanghai Mental Health Center
Shanghai, China Recruiting
Study contacts
- Study coordinator: Jiang Du, MD, PhD.
- Email: dujiangdou@163.com
- Phone: +8602164906315
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Imaging Mitochondrial Complex-I and Brain Metabolism in Alcohol Use Disorder
This study tests whether PET imaging with [18F]BCPP-EF and [18F]FDG can reveal differences in brain energy use between adults with alcohol use disorder and healthy controls, and whether these measures relate to relapse risk.
-
Endurance exercise to see if it lowers alcohol use in adults with AUD and ALD
A 12-week home-based cycling program added to standard care is tested to see if it reduces alcohol use and cravings in adults with alcohol use disorder and alcohol-related liver disease.
-
Do beverage cues drive craving in adults with AUD
In adults with alcohol use disorder, this study tests whether different non-alcoholic beverage cues can trigger cravings differently when people see and smell them without drinking.
-
Semaglutide for Alcohol Use Disorder and Obesity: Testing 1.0 mg and 2.0 mg vs Placebo
We’re testing two doses of semaglutide to see if they reduce alcohol craving and use in adults with alcohol use disorder and obesity compared with placebo.
-
TRIS: a mobile app with breathalyzer to support sobriety in alcohol use disorder
A smartphone app with a connected breathalyzer tests for abstinence and uses small financial incentives to encourage sobriety for adults with AUD in Brazil.
-
Body-focused mindfulness added to inpatient alcohol use disorder treatment
This trial tests whether a body-focused mindfulness program can help people with alcohol use disorder feel more connected to their bodies and reduce cravings while in inpatient care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.